Ipratropium/Salbutamol Comparator Versus Originator for Chronic Obstructive Pulmonary Disease Exacerbations: USA Observational Cohort Study Using the Clinformatics™ Health Claims Database

Thomas, Vicky; Gefen, Eran; Gopalan, Gokul; Marés, Rafael; McDonald, Rosie; Ming, Simon Wan Yau; Price, David

doi:10.1007/s41030-017-0041-7

Cited by 1 publication

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combination of SABA and SAMA led to improved lung function, as evidenced by a significant increase in post-bronchodilator Forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) ratio while minimising the occurrence of drug side effects. This combination can also reduce morbidity in patients with two synergistic bronchodilators to increase the stability of the respiratory tract (Thomas et al, 2017).…”

Section: Discussionmentioning

confidence: 99%

Therapy pattern of bronchodilators in chronic obstructive pulmonary disease (COPD) patients with acute exacerbations

Samirah,

Aryani,

Puspitasari

et al. 2023

Pharm Educ

View full text Add to dashboard Cite

Background: Acute exacerbation of chronic obstructive pulmonary disease (COPD) is a worsening condition of acute respiratory symptoms caused by microbial infection, increased air pollution, and fatigue. Objective: This study determines the pattern of bronchodilators in patients with acute exacerbations of COPD. Method: This study was observational, using the health medical records of patients with COPD at the Universitas Airlangga Hospital, Surabaya. It was conducted between January-December 2019 on male patients who received bronchodilator therapy until discharge and were from age 40 and older. Result: A total of 48 patients met the inclusion criteria. The most commonly used bronchodilator therapy for inpatients was the combination of ipratropium bromide/salbutamol sulfate 0.5 mg/2.5 mg through inhalation in 63.64%. The most frequently used bronchodilator for discharge was salbutamol sulfate 2-4 mg orally in 87.50%. Conclusion: Therapy for acute exacerbation of COPD using a combination of ipratropium bromide/salbutamol sulfate as a preventive therapy is in line with the GOLD guidelines.

show abstract

Section: Discussionmentioning

confidence: 99%